Key Takeaways
- CMS announced a final 2.48% Medicare Advantage payment rate increase for 2027, dramatically exceeding the 0.09% preliminary rate floated in January.
- Humana (HUM) shares skyrocketed 12% in after-hours trading, while UnitedHealth (UNH) and CVS Health (CVS) climbed more than 6% before the opening bell.
- The revised rate equates to approximately $13 billion in extra Medicare Advantage revenue for private insurers in 2027.
- Other healthcare stocks participated in the rally, including Molina Healthcare (MOH) with a 7% gain and Centene (CNC) up 4%.
- Mizuho’s Jared Holz called the rate “certainly better than the government’s initial rate decision,” though cautioned it’s not remarkably strong in isolation.
Humana (HUM) shares opened roughly 11% higher on Tuesday morning after Monday’s after-hours disclosure of finalized Medicare Advantage reimbursement rates for 2027.
The approved 2.48% rate represents a dramatic turnaround from the 0.09% preliminary figure released in January, which stunned industry participants and triggered selloffs in health insurance equities.
The CMS decision translates to over $13 billion in incremental Medicare Advantage reimbursements flowing to private health insurance companies during 2027.
UnitedHealth (UNH) and CVS Health (CVS), Aetna’s parent company, each posted premarket gains exceeding 6% on Tuesday. Elevance Health (ELV) advanced approximately 5%. Healthcare provider and managed care stocks also participated in the upswing, with Molina Healthcare (MOH) climbing 7% and Centene (CNC) gaining 4%.
The stock surge follows intensive industry advocacy spanning several months, during which insurers and their lobbying organizations contended that January’s proposal ignored escalating healthcare expenses. The Better Medicare Alliance characterized the near-zero preliminary rate as effectively a “cut,” highlighting that medical cost inflation has been running between 7% and 9% annually.
Key Adjustments in the Final Decision
Beyond the headline rate, CMS implemented several technical modifications. Beginning in 2027, the agency will eliminate diagnosis codes from unlinked chart review records when computing risk scores, though an exception applies for beneficiaries transitioning between Medicare Advantage carriers.
According to the agency, this policy shift will disproportionately affect plans that depend extensively on such chart reviews for documenting patient conditions and securing elevated reimbursements. CMS additionally refreshed the Part D risk adjustment framework to reflect provisions in the Inflation Reduction Act.
CMS Administrator Dr. Mehmet Oz stated the revisions are designed to maintain “coverage affordable” while ensuring enrollees receive “real value from their plans.”
Market analysts had adopted a conservative stance ahead of Monday’s revelation. TD Cowen’s Ryan Langston had projected a more moderate increase in the 1% to 1.5% territory. The 2.48% result surpassed those forecasts, although Mizuho’s Jared Holz offered measured commentary: “We do not believe a Medicare rate increase of 2.5% is so awesome in a vacuum, but is certainly better than the government’s initial rate decision.”
Holz indicated there is now “a chance for margins to expand next year, provided the Companies continue to trim benefits and align costs with revenue.”
Why This Rate Matters
Medicare Advantage serves approximately 35 million beneficiaries and has experienced consistent expansion, now exceeding enrollment in conventional government-administered Medicare. The finalized rate determines the distribution of more than half a trillion dollars through private health insurance plans annually, establishing it as among the most scrutinized metrics in the health insurance industry.
The rate incorporates variables including fundamental cost inflation, 2026 Star Ratings determining quality-based bonus payments, and revisions to risk adjustment calculations. CMS verified it will maintain the 2024 Medicare Advantage risk adjustment framework through 2027.
Cross-party concerns regarding Medicare Advantage expenditures had introduced ambiguity into the rate-setting process. Legislators from both sides have questioned insurer documentation methods that can generate elevated payments for patients with extensively recorded diagnoses. The Biden administration’s CMS had already begun constraining those payments, and January’s proposal under the Trump administration indicated that oversight would persist.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
